Evaluation of the Abbott ARCHITECT Chagas prototype assay

Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change?

“…1). The higher sensitivity of the Architect Chagas is probably due to the greater diversity of proteins used as antigens, representing the three morphological forms (trypomastigotes, epimastigotes, and amastigotes) and the genetic diversity of T. cruzi (26,45). Among current tests in which the number of recombinant proteins is known, the Architect Chagas uses the most.…”

“…Moreover, T. cruzi is currently divided into six DTUs with distinct genetic profiles (24). The Architect Chagas is capable of detecting the genetic diversity of T. cruzi by the incorporation of highly conserved antigenic proteins with tandemly repeated amino acid domains (26,45).…”

“…The lack of a reference standard serological assay for the diagnosis of T. cruzi infection has prompted the development of new tests, which require further evaluation. Among them, the Architect Chagas, a fully automated assay using four recombinant proteins as the antigen, has been scarcely studied to date (26)(27)(28).…”

“…Other advantages of new-generation tests are automation, rapidity, and high performance. Among them, the Architect Chagas (Abbott Laboratories, Wiesbaden, Germany), a chemiluminescent microparticle immunoassay (CMIA), uses four recombinant proteins as the antigen (26)(27)(28).…”

Advances in Serological Diagnosis of Chagas' Disease by Using Recombinant Proteins

“…Recently, Abbot Laboratories have presented a new kit which uses a 4-antigen multiepitope protein containing TcF, FP3 -built up with TcR27 and FcaBP-, FP6 -with TcR39 and FRA-and FP10 -with SAPA and MAP-. (Praast et al, 2011) According to the authors, this kit performed even better than the Biolab Merieux one. …”